Call Options

6 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2019

Nov 12, 2019

SELL
$140.29 - $189.96 $3.13 Million - $4.24 Million
-22,300 Closed
0 $0
Q2 2019

Aug 12, 2019

SELL
$157.85 - $183.09 $7.47 Million - $8.66 Million
-47,300 Reduced 67.96%
22,300 $4.08 Million
Q1 2019

May 10, 2019

BUY
$89.33 - $163.65 $2.55 Million - $4.68 Million
28,600 Added 69.76%
69,600 $11.1 Million
Q4 2018

Feb 13, 2019

BUY
$81.94 - $139.71 $81,940 - $139,710
1,000 Added 2.5%
41,000 $3.93 Million
Q3 2018

Nov 09, 2018

BUY
$138.11 - $169.04 $1.08 Million - $1.32 Million
7,800 Added 24.22%
40,000 $5.65 Million
Q2 2018

Aug 08, 2018

BUY
$140.36 - $175.76 $4.52 Million - $5.66 Million
32,200 New
32,200 $5.04 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $326M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Twin Tree Management, LP Portfolio

Follow Twin Tree Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Twin Tree Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Twin Tree Management, LP with notifications on news.